Analysis of factors associated with blood pressure reductions in hypertensive patients treated with esaxerenone -Integrated analysis from esaxerenone clinical studies
Not Applicable
- Conditions
- Hypertension
- Registration Number
- JPRN-UMIN000051525
- Lead Sponsor
- Daiichi Sankyo Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 493
Inclusion Criteria
Not provided
Exclusion Criteria
Not applicable
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Factors associated with change in morning BP (systolic BP and diastolic BP) from baseline to end of treatment (Week 12)
- Secondary Outcome Measures
Name Time Method Secondary endpoint; Factors associated with change in bedtime BP and office sitting BP (systolic BP and diastolic BP) from baseline to end of treatment (Week 12) Safety endpoint; Factors associated with number of patients with serum potassium elevation (5.5 mEq/L and more) to Week 12